Adjuvant Ipilimumab Improves OS in High-risk Stage III Melanoma

Share this content:
Adjuvant treatment with ipilimumab significantly improved overall survival among patients with high-risk, stage III melanoma.
Adjuvant treatment with ipilimumab significantly improved overall survival among patients with high-risk, stage III melanoma.

Adjuvant treatment with ipilimumab significantly improved overall survival, in contrast with placebo, among patients with high-risk, stage III melanoma.

The U.S. Food and Drug Administration approved ipilimumab for stage III melanoma in 2015 based on a study that demonstrated ipilimumab significantly improves recurrence-free survival. At the European Society for Medical Oncology (ESMO) 2016 Congress, researchers reported the impact of ipilimumab on overall survival and distant metastasis-free survival in this patient population.1

For the phase 3 study (ClinicalTrials.gov Identifier: NCT00636168), researchers enrolled 951 patients who underwent complete resection of stage III cutaneous melanoma. Of those, 20%, 44%, and 36% had stage IIIA, IIIB, and IIIC disease, respectively.

All participants were randomly assigned 1:1 to receive ipilimumab or placebo every 3 weeks for 4 doses, then every 3 months for up to 3 years until completion, disease recurrence, or unacceptable toxicity.

At a median follow-up of 5.3 years, results showed that ipilimumab significantly reduced the risk of death by 28% compared with placebo (hazard ratio [HR], 0.72; 95% CI, 0.58-0.88; P = .001).

Investigators also found that treatment with ipilimumab significantly reduced both recurrence-free survival (HR, 0.76; 95% CI, 0.64-0.89; P = .0008) and distant metastasis-free survival (HR, 0.76; 95% CI, 0.64-0.92; P = .002) by 24% versus placebo.

RELATED: Psychoeducational Intervention Effective Among Patients With Melanoma

The rates of grade 3 to 4 adverse events were 54.1% with ipilimumab and 26.2% with placebo, which were consistent with previous reports.

The most common grade 3 to 4 immune-related adverse events among patients treated with ipilimumab were gastrointestinal, hepatic, and endocrine. A total of 53.3% of patients who received ipilimumab discontinued treatment due to adverse events and 1.1% died due to treatment-related toxicities.

These findings highlight the utility of adjuvant ipilimumab therapy as a treatment option for patients with high-risk, stage III melanoma.                                   

Reference

  1. Eggermont AM, Chiarion-Sileni V, Grob J, et al. Ipilimumab (IPI) vs placebo (PBO) after complete resection of stage III melanoma: final overall survival results from the EORTC 18071 randomized, double-blind, phase 3 trial. Paper presented at: European Society for Medical Oncology (ESMO) 2016 Congress; October 7-11, 2016; Copenhagen, Denmark.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs